ZNF283 Inhibitors
Chemical inhibitors of ZNF283 can modulate the protein's activity through various molecular mechanisms. Palbociclib, as a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, can disrupt the phosphorylation state of proteins that interact with or regulate ZNF283, leading to its functional inhibition. This disruption can prevent ZNF283 from executing its role in the cell cycle. Similarly, Alsterpaullone, by inhibiting other cyclin-dependent kinases, can reduce the phosphorylation and activity of proteins that regulate ZNF283. Trichostatin A, by inhibiting histone deacetylase, can alter chromatin structure and, consequently, the DNA binding ability of ZNF283, while MG132, as a proteasome inhibitor, can increase the levels of regulatory proteins that inhibit ZNF283 function by blocking their degradation.
Furthermore, LY294002, a PI3K inhibitor, can disrupt interactions between ZNF283 and PI3K-pathway-related proteins, affecting the protein's regulatory mechanisms. Rapamycin's inhibition of the mTOR pathway can impair the regulatory mechanisms controlling ZNF283 function. SB203580 and PD98059, respectively inhibiting p38 MAP kinase and MEK1/2, can alter signaling pathways that normally regulate the functional activity of ZNF283. SP600125, as a JNK inhibitor, can disrupt regulatory mechanisms that control ZNF283. GW5074, by inhibiting c-Raf kinase, can disrupt signaling pathways that regulate ZNF283. Bortezomib, another proteasome inhibitor, can stabilize proteins that suppress ZNF283's function. Lastly, Mitoxantrone, through its inhibition of topoisomerase II, can impair molecular interactions and regulatory processes necessary for the functional activity of ZNF283.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. ZNF283 may be regulated through cell cycle-dependent mechanisms that involve CDKs. By inhibiting CDK4/6, Palbociclib could disrupt the phosphorylation state of proteins that interact with or regulate ZNF283, leading to its functional inhibition. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. ZNF283, as a zinc finger protein, may interact with chromatin for DNA binding. By altering the acetylation state of histones, Trichostatin A could change the chromatin structure and thus inhibit the DNA binding ability of ZNF283. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of proteins. By inhibiting the proteasome, MG132 might increase the levels of regulatory proteins that can sequester ZNF283 or inhibit its function, leading to the functional inhibition of ZNF283. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and PI3K signaling is crucial for many cellular processes. If ZNF283 is regulated by PI3K-pathway-related proteins, LY294002 could disrupt these interactions, leading to functional inhibition of ZNF283. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is involved in the regulation of protein synthesis and various cellular processes. Inhibition of mTOR could impair the regulatory mechanisms controlling ZNF283 function, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, and p38 MAP kinase is involved in signaling pathways that regulate protein function. Inhibition of p38 MAP kinase could lead to functional inhibition of ZNF283 through disruption of these regulatory pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Since ZNF283 may be regulated by MAPK/ERK signaling, inhibition of MEK by PD98059 could inhibit the functional activity of ZNF283. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK signaling affects transcription factors and regulatory proteins. By inhibiting JNK, SP600125 could disrupt regulatory mechanisms that control the functional activity of ZNF283. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor, potentially affecting cell cycle and transcription factor regulation. Inhibition of these kinases could reduce the phosphorylation and activity of proteins that regulate ZNF283, leading to its inhibition. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a c-Raf kinase inhibitor, and c-Raf is part of the MAPK/ERK pathway. Inhibiting c-Raf with GW5074 could disrupt signaling that regulates ZNF283, leading to functional inhibition of the protein. | ||||||